Literature DB >> 11123854

Herbs and atherosclerosis.

D Heber1.   

Abstract

It is now widely accepted that atherosclerosis is a complex multicellular process involving oxidation of cholesterol and the intracellular accumulation of oxidized cholesterol. This accumulation causes a cascade of inflammatory processes, resulting in an unstable atherosclerotic plaque that ultimately bursts, causing myocardial infarction. Botanical dietary supplements (herbs) can ameliorate this process and prevent cardiovascular disease at many steps in the process. Many herbs have antioxidant activity and can reduce low-density lipoprotein oxidation. Some phytosterols found in botanicals can inhibit cholesterol absorption. After a brief review of herbs being promoted for achieving and maintaining healthy cholesterol levels, the evidence and future prospects for Chinese red yeast rice, the main component of dietary supplements with HMG-CoA reductase inhibiting activity, are discussed in detail. Initial phase II clinical trials are highly encouraging. This herb is likely to be able to directly impact the process of atherosclerosis, but large-scale clinical trials are needed to assess the public health potential of this herbal supplement.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11123854     DOI: 10.1007/s11883-001-0016-9

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  9 in total

1.  Lipid-lowering therapy in low-risk patients.

Authors:  T A Pearson
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

2.  Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?

Authors:  S Perreault; V H Hamilton; F Lavoie; S Grover
Journal:  Arch Intern Med       Date:  1998-02-23

3.  Monacolin K, a new hypocholesterolemic agent produced by a Monascus species.

Authors:  A Endo
Journal:  J Antibiot (Tokyo)       Date:  1979-08       Impact factor: 2.649

4.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

5.  Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement.

Authors:  D Heber; I Yip; J M Ashley; D A Elashoff; R M Elashoff; V L Go
Journal:  Am J Clin Nutr       Date:  1999-02       Impact factor: 7.045

6.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

7.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

8.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up.

Authors:  R H Bradford; C L Shear; A N Chremos; C A Dujovne; F A Franklin; R B Grillo; J Higgins; A Langendorfer; D T Nash; J L Pool
Journal:  Am J Cardiol       Date:  1994-10-01       Impact factor: 2.778

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

  9 in total
  7 in total

1.  A vascular-liver chip for sensitive detection of nutraceutical metabolites from human pluripotent stem cell derivatives.

Authors:  Fang Yu; Yeek Teck Goh; Huan Li; Narmada Balakrishnan Chakrapani; Ming Ni; Guo Lin Xu; Tseng-Ming Hsieh; Yi-Chin Toh; Christine Cheung; Ciprian Iliescu; Hanry Yu
Journal:  Biomicrofluidics       Date:  2020-05-27       Impact factor: 2.800

Review 2.  Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach.

Authors:  Jie Wang; Xingjiang Xiong; Bo Feng
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-29       Impact factor: 2.629

3.  Salvia fruticosa Induces Vasorelaxation In Rat Isolated Thoracic Aorta: Role of the PI3K/Akt/eNOS/NO/cGMP Signaling Pathway.

Authors:  M Akhtar Anwar; Ali A Samaha; Samar Ballan; Alaaeldin I Saleh; Rabah Iratni; Ali H Eid
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

4.  Human Stem Cell-Derived Endothelial-Hepatic Platform for Efficacy Testing of Vascular-Protective Metabolites from Nutraceuticals.

Authors:  Balakrishnan Chakrapani Narmada; Yeek Teck Goh; Huan Li; Sanjay Sinha; Hanry Yu; Christine Cheung
Journal:  Stem Cells Transl Med       Date:  2016-10-07       Impact factor: 6.940

Review 5.  Nanoformulations of natural products for management of metabolic syndrome.

Authors:  Yasamin Davatgaran Taghipour; Marziyeh Hajialyani; Rozita Naseri; Mahvash Hesari; Pantea Mohammadi; Azzurra Stefanucci; Adriano Mollica; Mohammad Hosein Farzaei; Mohammad Abdollahi
Journal:  Int J Nanomedicine       Date:  2019-07-16

Review 6.  Natural Products to Counteract the Epidemic of Cardiovascular and Metabolic Disorders.

Authors:  Birgit Waltenberger; Andrei Mocan; Karel Šmejkal; Elke H Heiss; Atanas G Atanasov
Journal:  Molecules       Date:  2016-06-22       Impact factor: 4.411

7.  Rhus coriaria L. (Sumac) Evokes Endothelium-Dependent Vasorelaxation of Rat Aorta: Involvement of the cAMP and cGMP Pathways.

Authors:  Mohammad A Anwar; Ali A Samaha; Safaa Baydoun; Rabah Iratni; Ali H Eid
Journal:  Front Pharmacol       Date:  2018-06-28       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.